Abstract :
The present study was aimed to develop transdermal drug delivery of Oxybutynin to overcome the first pass
metabolism and to reduce frequency of dosing compared to oral route. Matrix type of transdermal patches was
developed by using polymers eudragit L100 and eudragit S100.Transdermal patches were prepared by employing
solvent casting method. Propylene glycol and Tween80 were selected as permeation enhancer and plasticizer. Drug
excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions.
Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the
formulations were evaluated for various physical parameters Physical appearance, Flatness, Weight variation,
Thickness, Folding endurance, Drug content, Moisture uptake, Moisture content and Swelling study and all the
results were found to be were found to be with in the pharmacopeial limits, invitro drug release studies by using
dialysis membrane. Among all the 12 formulations F6 formulation which contain HPMC K4M 300mg and Eudragit
L-100 60mg had shown 94% cumulative drug release with in 12 hours. And compared to HPMC K15M, HPMC
K4M showed better drug release profile. For F6 formulation release kinetics were plotted and the Regression
coefficient value was found to be high for Korsmeyer-peppas release model i.e., 0.9892. The n value was found to be
0.6203 which indicates the drug release pattern was found to be non-Fickian diffusion.
Key words: Oxybutynin, Matrix type, Transdermal patches
Keyword :
Oxybutynin, Matrix type, Transdermal patches